Byondis’ ADC Candidate Shows Prolonged PFS in HER-2+ Advanced Breast Cancer,

The company is currently investigating SYD985 in four other clinical trials, including a Phase II trial in HER2-expressing recurrent, advanced or …, The company is currently investigating SYD985 in four other clinical trials, including a Phase II trial in HER2-expressing recurrent, advanced or …, Read More

Scroll to Top